Regeneca Announces Response to FDA Warning Letter
Regeneca, Inc. (Pink Sheets:RGNA - News) has submitted a Response Letter to the FDA Warning Letter received on May 27, 2011. The letter outlines the actions taken by Regeneca to ensure the compliance of its products and marketing materials related to RegenErect, Regeneca's male enhancement product.
Regeneca's CEO Matt Nicosia commented, "We feel that we have taken all of the necessary steps to address the issues and concerns in the warning letter received from the FDA. The male enhancement market in the United States continues to grow. The fact is that most males over the age of 25 experience decreased sexual performance, and there is considerable demand for natural male enhancement products. Our product, RegenErect, is positioned to take advantage of this market need through our Direct Response Network Marketing model."
About RegenErect
RegenErect is an all-natural dietary supplement that enhances the sexual experience 365 days a year with no adverse side effects. More information can found about RegenErect at www.regenerect.com.
About Regeneca, Inc.
Regeneca, Inc. (Pink Sheets:RGNA - News) was formed to create and commercialize premium products that help to improve health and fight the signs and symptoms of aging for a complete life of wellness and happiness, including our natural male enhancement product - RegenErect. We do this while drawing our products from the earth in an ethical strategy that will emphasize regrowth, reforestation and recycling. This is our "Whole Earth Whole Body" approach to health. More information can be found about Regeneca, Inc. at www.regeneca.com.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements, including, but not limited to, statements regarding Regeneca, Inc. and their plans, products and related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Regeneca, Inc.'s filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Regeneca undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
Related News
-
Regeneca Shutting Down
Regeneca Worldwide has been ordered to cease operations by the Department of Justice, which filed a consent decree of permanent injunction against the company and its CEO, Matthew Nicosia, alleging that they violated the Federal Food, Drug and Cosmetic Act (FDCA) by manufacturing and distributing Re... Read More...Regeneca Given Distribution Rights for CardioMap
Cottonwood Heights, UT June 11, 2015 -- Regeneca Worldwide has entered into an exclusive distribution agreement with VE Science Technologies LLC, the creators of the CardioMap heart screening and monitor device, for the network marketing industry."We are very excited about this deal, as the ... Read More...
Regeneca Worldwide Announces New President
Cottonwood Heights, UT May 14, 2015 -- Regeneca Worldwide has concluded their search for a new President and are pleased to announce that Mr. Trent Staggs will now lead the company in this role."We are thrilled to have Trent Staggs join the Regeneca team and lead the company's operations," s... Read More...
Regeneca Worldwide Recalls RegenESlim Capsules
Inc. Las Vegas, NV is conducting a voluntary nationwide recall of its RegenESlim appetite control dietary supplement from lot # EX0616R15814 and lot #11414RE5516 because FDA analysis confirmed the presence of DMAA. DMAA is also known as 1,3-dimethylamylamine, methylhexanamine, or geranium extract. ... Read More...
